-
Comprehensive Weight Loss Programs at Ivím Health: Flexible Memberships with GLP-1 Medications and Klarna Payments
FDA notice on Zepbound™/Mounjaro® shortage: On December 19th, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Patients may continue receiving essential copies through […]
-
Zepbound® (tirzepatide) Dosage Charts: A Comprehensive Guide
FDA notice on Zepbound®/Mounjaro® shortage: The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Schedule a visit with an Ivim provider to discuss what this […]
-
What Is Ivím Health’s Online Weight Loss Program Membership?
At Ivím Health, our mission is to deliver unparalleled, personalized care that goes far beyond basic healthcare—and our membership model allows us to do just that. We’re proud to offer so much more than just weight loss […]
-
Semaglutide Weight Loss Dosage Chart: Everything You Need to Know
FDA notice on Wegovy®/Ozempic® shortage: On February 21st, 2025, the U.S. Food and Drug Administration determined that the shortage of semaglutide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Patients may continue receiving essential copies through […]
-
Ivím Provider Completes Medical Mission Trip to Promote Health and Foster Community
At Ivím, our mission is to build health and foster community, not just within our own organization, but across the globe. We are proud to have dedicated providers like Arielle Gelardi, NP, who embody this mission through […]
-
Support for a Successful Weight Loss Transformation
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim […]
-
The Benefits of Ozempic® (semaglutide) for Weight Loss
Initially developed as a treatment for type 2 diabetes, Ozempic® (semaglutide) has emerged as a transformative solution for weight loss. Semaglutide, the active ingredient in Ozempic®, has shown significant results in clinical trials. Research reveals that adults […]
-
GLP-1s and Nutrition: What You Need to Know
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim […]
-
Designing Your Weight Loss Journey Around Healthy Habits
While GLP-1 medication provides a phenomenal jumpstart for a weight loss journey, an integral part of achieving long-term results is developing healthy habits along the way. Diet and exercise are two common goals people set to improve, […]
-
The Landscape of Weight Loss Medications: An Overview
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim […]
Services
Company
Support
Legal
